Advertisement

Journal of Gastroenterology

, Volume 46, Issue 3, pp 359–366 | Cite as

A novel transcatheter arterial infusion chemotherapy using iodized oil and degradable starch microspheres for hepatocellular carcinoma: a prospective randomized trial

  • Takahiro YamasakiEmail author
  • Satoe Hamabe
  • Issei Saeki
  • Yohei Harima
  • Yuhki Yamaguchi
  • Koichi Uchida
  • Shuji Terai
  • Isao Sakaida
Original Article—Liver, Pancreas, and Biliary Tract

Abstract

Background

We designed a novel transcatheter arterial infusion chemotherapy (TAI) using iodized oil (lipiodol) and degradable starch microspheres (DSM) for hepatocellular carcinoma (HCC) patients. In this study, we investigated the efficacy of TAI using lipiodol and DSM in a prospective randomized trial.

Methods

We randomly divided 45 patients with HCC into 3 groups: TAI using lipiodol (lipiodol group, n = 15), TAI using DSM (DSM group, n = 15), and TAI using lipiodol and DSM (lipiodol + DSM group, n = 15). In the lipiodol group, a mixture of cisplatin and lipiodol was administered. In the DSM group, a mixture of cisplatin and DSM was administered. In the lipiodol + DSM group, a mixture of cisplatin and lipiodol was administered, followed by DSM.

Results

The response rates were 40% in the lipiodol group, 53.4% in the DSM group, and 80% in the lipiodol + DSM group, respectively. The response rate tended to improve in the lipiodol + DSM group (lipiodol group vs. lipiodol + DSM group, P = 0.07). The median progression-free survival time was 177 days in the lipiodol group, 287 days in the DSM group, and 377 days in the lipiodol + DSM group. The progression-free survival in the lipiodol + DSM group was significantly better than those in the DSM group (P = 0.020) and the lipiodol group (P = 0.035). There were no serious adverse effects among the 3 groups.

Conclusions

TAI using lipiodol and DSM was superior to TAI using lipiodol only and TAI using DSM only because of improvements in therapeutic effects and progression-free survival.

Keywords

Hepatocellular carcinoma Transcatheter arterial infusion chemotherapy Iodized oil Degradable starch microspheres Randomized trial 

Notes

Acknowledgment

This study was supported by a grant-in-aid for scientific research from the Japan Society for the Promotion of Science (Grant No. 20591478).

References

  1. 1.
    Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24:2137–50.PubMedCrossRefGoogle Scholar
  2. 2.
    Kiyosawa K, Umemura T, Ichijo T, Matsumoto A, Yoshizawa K, Gad A, et al. Hepatocellular carcinoma: recent trends in Japan. Gastroenterology. 2004;127:S17–26.PubMedCrossRefGoogle Scholar
  3. 3.
    El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology. 2004;127:S27–34.PubMedCrossRefGoogle Scholar
  4. 4.
    Bosetti C, Levi F, Boffetta P, Lucchini F, Negri E, La Vecchia C. Trends in mortality from hepatocellular carcinoma in Europe. 1980–2004. Hepatology. 2008;48:137–45.PubMedCrossRefGoogle Scholar
  5. 5.
    El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology. 2008;134:1752–63.PubMedCrossRefGoogle Scholar
  6. 6.
    Ebara M, Okabe S, Kita K, Sugiura N, Fukuda H, Yoshikawa M, et al. Percutaneous ethanol injection for small hepatocellular carcinoma: therapeutic efficacy based on 20-year observation. J Hepatol. 2005;43:458–64.PubMedCrossRefGoogle Scholar
  7. 7.
    Matsui O, Kadoya M, Yoshikawa J, Gabata T, Arai K, Demachi H, et al. Small hepatocellular carcinoma: treatment with subsegmental transcatheter arterial embolization. Radiology. 1993;188:79–83.PubMedGoogle Scholar
  8. 8.
    Yamasaki T, Kurokawa F, Shirahashi H, Kusano N, Hironaka K, Okita K. Percutaneous radiofrequency ablation therapy with combined angiography and computed tomography assistance for patients with hepatocellular carcinoma. Cancer. 2001;91:1342–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Todo S, Furukawa H, Japanese Study Group on Organ Transplantation. Living donor liver transplantation for adult patients with hepatocellular carcinoma: experience in Japan. Ann Surg. 2004;240:451–61.PubMedCrossRefGoogle Scholar
  10. 10.
    Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–90.PubMedCrossRefGoogle Scholar
  11. 11.
    Takayasu K, Arii S, Ikai I, Omata M, Okita K, Ichida T, et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology. 2006;131:461–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Marelli L, Stigliano R, Triantos C, Senzolo M, Cholongitas E, Davies N, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol. 2007;30:6–25.PubMedCrossRefGoogle Scholar
  13. 13.
    Bruix J, Llovet JM, Castells A, Montañá X, Brú C, Ayuso MC, et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology. 1998;27:1578–83.PubMedCrossRefGoogle Scholar
  14. 14.
    Pelletier G, Ducreux M, Gay F, Luboinski M, Hagège H, Thong D, et al. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. J Hepatol. 1998;29:129–34.PubMedCrossRefGoogle Scholar
  15. 15.
    Cammà C, Schepis F, Orlando A, Albanese M, Shahied L, Trevisani F, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology. 2002;224:47–54.PubMedCrossRefGoogle Scholar
  16. 16.
    Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003;37:429–42.PubMedCrossRefGoogle Scholar
  17. 17.
    Takayasu K, Muramatsu Y, Maeda T, Iwata R, Furukawa H, Moriyama N, et al. Targeted transarterial oily chemoembolization for small foci of hepatocellular carcinoma using a unified helical CT and angiography system: analysis of factors affecting local recurrence and survival rates. AJR Am J Roentgenol. 2001;176:681–8.PubMedGoogle Scholar
  18. 18.
    Yoon HJ, Kim JH, Kim KA, Lee IS, Ko GY, Song HY, et al. Transcatheter arterial chemo-lipiodol infusion for unresectable hepatocellular carcinoma in 96 high-risk patients. Clin Radiol. 2010;65:271–7.PubMedCrossRefGoogle Scholar
  19. 19.
    Ikeda M, Maeda S, Shibata J, Muta R, Ashihara H, Tanaka M, et al. Transcatheter arterial chemotherapy with and without embolization in patients with hepatocellular carcinoma. Oncology. 2004;66:24–31.PubMedCrossRefGoogle Scholar
  20. 20.
    Forsberg JO. Transient blood flow reduction induced by intra-arterial injection of degradable starch microspheres. Experiments on rats. Acta Chir Scand. 1978;144:275–81.PubMedGoogle Scholar
  21. 21.
    Lindell B, Aronsen KF, Rothman U. Repeated arterial embolization of rat livers by degradable microspheres. Eur Surg Res. 1977;9:347–56.PubMedCrossRefGoogle Scholar
  22. 22.
    Dakhil S, Ensminger W, Cho K, Niederhuber J, Doan K, Wheeler R. Improved regional selectivity of hepatic arterial BCNU with degradable microspheres. Cancer. 1982;50:631–5.PubMedCrossRefGoogle Scholar
  23. 23.
    Ensminger WD, Gyves JW, Stetson P, Walker-Andrews S. Phase I study of hepatic arterial degradable starch microspheres and mitomycin. Cancer Res. 1985;45:4464–7.PubMedGoogle Scholar
  24. 24.
    Taguchi T. Chemo-occlusion for the treatment of liver cancer. A new technique using degradable starch microspheres. Clin Pharmacokinet. 1994;26:275–91.PubMedCrossRefGoogle Scholar
  25. 25.
    Carr BI, Zajiko A, Bron K, Orons P, Sammon J, Baron R. Phase II study of Spherex (degradable starch microspheres) injected into the hepatic artery in conjunction with doxorubicin and cisplatin in the treatment of advanced-stage hepatocellular carcinoma: interim analysis. Semin Oncol. 1997;24(suppl 6):S6-97–9.Google Scholar
  26. 26.
    Furuse J, Ishii H, Satake M, Onaya H, Nose H, Mikami S, et al. Pilot study of transcatheter arterial chemoembolization with degradable starch microspheres in patients with hepatocellular carcinoma. Am J Clin Oncol. 2003;26:159–64.PubMedCrossRefGoogle Scholar
  27. 27.
    Kirchhoff TD, Rudolph KL, Layer G, Chavan A, Greten TF, Rosenthal H, et al. Chemoocclusion vs. chemoperfusion for treatment of advanced hepatocellular carcinoma: a randomised trial. Eur J Surg Oncol. 2006;32:201–7.PubMedCrossRefGoogle Scholar
  28. 28.
    Yamasaki T, Saeki I, Harima Y, Okita K, Segawa M, Yamaguchi Y, et al. The pilot study: a novel transarterial chemoembolization using degradable starch microspheres for hepatocellular carcinoma (in Japanese with English abstract). Kanzo. 2008;49:25–7.CrossRefGoogle Scholar
  29. 29.
    Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649–55.PubMedCrossRefGoogle Scholar
  30. 30.
    Liver Cancer Study Group of Japan. The General Rules for the Clinical and Pathological Study of Primary Liver Cancer, 5th edn. Tokyo: Kanehara, 2009 (in Japanese).Google Scholar
  31. 31.
    Kudo M, Chung H, Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol. 2003;38:207–15.PubMedCrossRefGoogle Scholar
  32. 32.
    Kanematsu M, Hoshi H, Imaeda T, Murakami T, Inaba Y, Yokoyama R, et al. Detection and characterization of hepatic tumors: value of combined helical CT hepatic arteriography and CT during arterial portography. AJR Am J Roentgenol. 1997;168:1193–8.PubMedGoogle Scholar
  33. 33.
    Okusaka T, Okada S, Ishii H, Ikeda M, Nakasuka H, Nagahama H, et al. Transarterial chemotherapy with zinostatin stimalamer for hepatocellular carcinoma. Oncology. 1998;55:276–83.PubMedCrossRefGoogle Scholar
  34. 34.
    Takayasu K, Arri S, Matsuo N, Yoshikawa M, Ryu M, Takasaki K, et al. Comparison of CT findings with resected specimens after chemoembolization with iodized oil for hepatocellular carcinoma. AJR Am J Roentgenol. 2000;175:699–704.PubMedGoogle Scholar
  35. 35.
    Okusaka T, Okada S, Ueno H, Ikeda M, Yoshimori M, Shimada K, et al. Evaluation of the therapeutic effect of transcatheter arterial embolization for hepatocellular carcinoma. Oncology. 2000;58:293–9.PubMedCrossRefGoogle Scholar
  36. 36.
    National Cancer Institute (2009) Common Terminology Criteria for Adverse Events v.4.0. National Cancer Institute, BethesdaGoogle Scholar
  37. 37.
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc. 1958;53:457–81.CrossRefGoogle Scholar
  38. 38.
    Ono Y, Yoshimasu T, Ashikaga R, Inoue M, Shindou H, Fuji K, et al. Long-term results of lipiodol-transcatheter arterial embolization with cisplatin or doxorubicin for unresectable hepatocellular carcinoma. Am J Clin Oncol. 2000;23:564–8.PubMedCrossRefGoogle Scholar
  39. 39.
    Yoshikawa M, Ono N, Yodono H, Ichida T, Nakamura H. Phase II study of hepatic arterial infusion of a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma. Hepatol Res. 2008;38:474–83.PubMedCrossRefGoogle Scholar
  40. 40.
    Vogl TJ, Trapp M, Shroeder H, Mack M, Schuster A, Schmitt J, et al. Transarterial chemoembolization for hepatocellular carcinoma: volumetric and morphologic CT criteria for assessment of prognosis and therapeutic success—results from a liver transplantation center. Radiology. 2000;214:349–57.Google Scholar
  41. 41.
    Kirchhoff TD, Bleck JS, Dettmer A, Chavan A, Rosenthal H, Merkesdal S, et al. Transarterial chemoembolization using degradable starch microspheres and iodized oil in the treatment of advanced hepatocellular carcinoma: evaluation of tumor response, toxicity, and survival. Hepatobiliary Pancreat Dis Int. 2007;6:259–66.PubMedGoogle Scholar
  42. 42.
    Kanematsu M. Transcatheter arterial chemoembolization therapy with epirubicin hydrochloride, mitomycin C-iohexol-lipiodol emulsion (EMILE) for hepatocellular carcinoma. J Gastroenterol. 1995;30:215–23.Google Scholar
  43. 43.
    Sigurdson ER, Ridge JA, Daly JM. Intra-arterial infusion of doxorubicin with degradable starch microspheres. Improvement of hepatic tumor drug uptake. Arch Surg. 1986;121:1277–81.PubMedCrossRefGoogle Scholar
  44. 44.
    Nakamura H, Hashimoto T, Oi H, Sawada S. Iodized oil in the portal vein after arterial embolization. Radiology. 1988;167:415–7.PubMedGoogle Scholar
  45. 45.
    Kan Z, Ivancev K, Hägerstrand I, Chuang VP, Lunderquist A. In vivo microscopy of the liver after injection of lipiodol into the hepatic artery and portal vein in the rat. Acta Radiol. 1989;30:419–25.PubMedCrossRefGoogle Scholar

Copyright information

© Springer 2010

Authors and Affiliations

  • Takahiro Yamasaki
    • 1
    Email author
  • Satoe Hamabe
    • 1
  • Issei Saeki
    • 1
  • Yohei Harima
    • 1
  • Yuhki Yamaguchi
    • 1
  • Koichi Uchida
    • 1
  • Shuji Terai
    • 1
  • Isao Sakaida
    • 1
  1. 1.Department of Gastroenterology and HepatologyYamaguchi University Graduate School of MedicineUbeJapan

Personalised recommendations